Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
April 11 2018 - 4:05PM
Business Wire
- Conference Call and Webcast to Follow at 5:00
p.m. EDT/ 2:00 p.m. PDT -
Exelixis, Inc. (NASDAQ: EXEL) announced today that its first
quarter 2018 financial results will be released on Wednesday, May
2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT,
Exelixis management will host a conference call and webcast to
discuss the results and provide a general business update. Access
to the event is available via the Internet from the company’s
website.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
listen to the webcast. Alternatively, please call 855-793-2457
(domestic) or 631-485-4921 (international) and provide the
conference call passcode 7895176 to join by phone.
A telephone replay will be available until 8:30 p.m. EDT on May
4, 2018. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is
7895176. A webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring these medicines to patients globally. We
are steadfast in our commitment to prudently reinvest in our
business to maximize the potential of our pipeline. We intend to
supplement our existing therapeutic assets with targeted business
development activities and internal drug discovery – all to deliver
the next generation of Exelixis medicines and help patients recover
stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program
honoring the 500 fastest-growing companies over the past four
years. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis and the Exelixis logo are registered
U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180411006318/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Executive Vice
President, Public Affairs & Investor
Relationsshubbard@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024